Human medicines European public assessment report (EPAR): Arexvy, Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Date of authorisation: 06/06/2023, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 20 August 2026 - 11:00

Human medicines European public assessment report (EPAR): Arexvy, Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Date of authorisation: 06/06/2023, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 16, Status: Authorised

Submitted by Anonymous (not verified) on 20 August 2026 - 10:42

Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Ryeqo, relugolix,estradiol,norethisterone acetate, Date of authorisation: 16/07/2021, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 20 August 2026 - 10:34

Human medicines European public assessment report (EPAR): Ryeqo, relugolix,estradiol,norethisterone acetate, Date of authorisation: 16/07/2021, Revision: 9, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More